Benitec Biopharma (NASDAQ:BNTC) Share Price Breaks Below 50-Day Moving Average – Here’s What HappenedDefense World · 4 days ago
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal StudyGlobeNewsWire · Oct 5, 2026
Benitec Biopharma (NASDAQ:BNTC) Stock Crosses Below 50 Day Moving Average – Here’s WhyDefense World · Sep 30, 2026
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)Zacks Investment Research · Sep 25, 2026
Benitec Biopharma (BNTC) Projected to Release Quarterly Earnings on MondayDefense World · Sep 21, 2026
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational UpdateGlobeNewsWire · Sep 14, 2026Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 14, 2026 | -$0.26 | -$0.26 | Beat |
| May 14, 2026 | -$0.27 | -$0.24 | Beat |
| Feb 12, 2026 | -$0.23 | -$0.26 | Miss |
| Nov 14, 2025 | -$0.35 | -$0.22 | Beat |
| Sep 22, 2025 | -$0.28 | -$0.42 | Miss |
| May 14, 2025 | -$0.36 | -$0.24 | Beat |